NYSE$GMED
Globus Medical Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Globus Medical's revenue decreased, resulting in a net loss, but non-GAAP EPS remained positive, and the company focused on strategic improvements during the second quarter.
Globus Medical reported a decrease in worldwide sales by 23.4% compared to the second quarter of 2019. The company experienced a net loss of $20.8 million, but non-GAAP diluted EPS was $0.07. Despite the challenges, Globus Medical focused on strengthening its business for future growth.
- Worldwide sales decreased by 23.4% year-over-year to $148.9 million.
- The company had a net loss of $20.8 million.
- Diluted EPS was $(0.21), while non-GAAP diluted EPS was $0.07.
- Non-GAAP adjusted EBITDA was 14.7% of sales.
Headline financials
Revenue & EPS history
Globus Medical · Revenue · Quarterly
$149M
Revenue by segment
Globus Medical · $149M total across 2 segments · Q2 2020
- Musculoskeletal Solutions$143M-21.4%96.3%
- Enabling Technologies$5.44M-54.7%3.7%
Forward guidance
Globus Medical withdrew its full year 2020 guidance due to the uncertainties related to the COVID-19 pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.8%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.9%
Avg return
30 days after
57%
34 / 60 earnings
Positive
+36.0%
Q3 2025
Best reaction
-23.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -14.6% | -10.4% | |
| Q4 2025 | +4.6% | +2.1% | -8.8% | |
| Q3 2025 | +36.0% | +37.3% | +47.6% | |
| Q1 2025 | -23.0% | -19.7% | -17.3% | |
| Q4 2024 | -4.6% | -4.9% | -12.5% | |
| Q3 2024 | +10.7% | +8.2% | +11.2% | |
| Q2 2024 | +4.0% | +8.0% | +4.4% | |
| Q1 2024 | +22.8% | +28.7% | +31.6% | |
| Q4 2023 | +2.2% | +4.6% | -3.1% | |
| Q3 2023 | -1.4% | -5.1% | -2.5% | |
| Q2 2023 | -5.0% | -4.8% | -9.1% | |
| Q1 2023 | +2.9% | -0.3% | -1.8% | |
| Q4 2022 | -1.2% | -21.9% | -29.2% | |
| Q3 2022 | -4.2% | +9.4% | +11.5% | |
| Q2 2022 | +5.4% | +6.9% | -2.4% | |
| Q1 2022 | +0.1% | +5.2% | +0.1% | |
| Q4 2021 | -3.1% | -3.7% | +1.3% | |
| Q3 2021 | +0.2% | -4.3% | -19.4% | |
| Q2 2021 | -3.3% | -3.0% | +1.3% | |
| Q1 2021 | +3.1% | +3.0% | -0.9% | |
| Q4 2020 | -5.7% | -5.2% | -10.2% | |
| Q3 2020 | +2.4% | +3.5% | +16.9% | |
| Q2 2020 | +18.5% | +13.4% | +13.3% | |
| Q1 2020 | +8.1% | +0.6% | +21.4% | |
| Q4 2019 | -2.1% | -9.7% | -29.0% | |
| Q3 2019 | +3.6% | +4.2% | +8.2% | |
| Q2 2019 | +9.9% | +6.1% | +12.0% | |
| Q1 2019 | -1.9% | -2.0% | -11.0% | |
| Q4 2018 | +0.2% | -2.2% | -0.3% | |
| Q3 2018 | -8.7% | -9.9% | -19.4% | |
| Q2 2018 | +4.7% | +1.7% | +3.5% | |
| Q1 2018 | -3.4% | +0.7% | +12.6% | |
| Q4 2017 | +0.5% | -1.8% | +2.2% | |
| Q3 2017 | +9.8% | +19.7% | +24.3% | |
| Q2 2017 | -5.2% | -3.7% | -1.7% | |
| Q1 2017 | +4.9% | +1.0% | +4.7% | |
| Q4 2016 | -3.1% | -2.1% | +2.5% | |
| Q3 2016 | -5.6% | -4.9% | +7.1% | |
| Q2 2016 | -14.3% | -11.7% | -13.1% | |
| Q1 2016 | -9.4% | — | — | |
| Q4 2015 | +4.2% | — | — | |
| Q3 2015 | +12.3% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +7.0% | — | — | |
| Q2 2014 | -16.8% | — | — | |
| Q1 2014 | +6.1% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | +7.1% | — | — | |
| Q2 2013 | +2.3% | — | — | |
| Q1 2013 | +7.9% | — | — | |
| Q1 2011 | +0.4% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2011 | -20.7% | — | — | |
| Q3 2012 | -16.2% | — | — | |
| Q4 2011 | -0.7% | — | — | |
| Q2 2011 | -0.7% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro